News >

Pegylated Doxorubicin/Carboplatin Plus Bevacizumab Improves PFS in Recurrent Ovarian Cancer

Wayne Kuznar
Published: Wednesday, Nov 14, 2018

Jacobus Pfisterer, MD, PhD

Jacobus Pfisterer, MD, PhD

The combination regimen of pegylated liposomal doxorubicin (CD-BEV) with bevacizumab (Avastin) was found to significantly improve progression-free survival (PFS) versus carboplatin/gemcitabine (CG-BEV) in patients with recurrent disease whose first recurrence was longer than 6 months following frontline platinum-based chemotherapy, according to phase III findings presented at the 2018 ESMO Congress.

There was also a trend toward an improvement in median overall survival (OS) with CD-BEV compared with CG-BEV that did not achieve significance (33.5 vs 28.2 months; HR, 0.833; 95% CI, 0.680-1.022; stratified log-rank P = .0787).

A total of 682 patients with recurrent ovarian cancer suitable for platinum-based retreatment were randomized 1:1 to standard treatment (CG-BEV) or the experimental treatment (CD-BEV). In the standard arm, bevacizumab was given as 15 mg/kg on day 1, followed by gemcitabine (1,000mg/m² on days 1 and 8) and carboplatin (AUC4 on day 1) every 3 weeks for up to 6 cycles in the absence of progression disease or unacceptable toxicities.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication